Mainolfi Nello 4

What Happened

• Nello Mainolfi, CEO of Kymera Therapeutics (KYMR), exercised 30,000 options (M) and paid $2.08 per share ($62,400 total), and sold 30,000 shares in the open market the same day for combined proceeds of approximately $2,435,377. The open-market sales were executed in three tranches (17,005; 12,059; 936 shares) at weighted-average prices reported in the filing. The filing also lists a disposal of 30,000 shares at $0.00 (derivative), as reported.

Key Details

• Transaction date: 2026-04-29 (all reported transactions).
• Exercise: 30,000 shares at $2.08 — cost $62,400.
• Open-market sales: 17,005 shares at a weighted avg $80.74; 12,059 shares at $81.70; 936 shares at $82.45. Total cash proceeds for these sales ≈ $2,435,377.
• Additional line: disposal of 30,000 derivative shares at $0.00 (filing reports $0 proceeds).
• Footnotes: Transactions were effected pursuant to a Rule 10b5-1 trading plan dated Sept 6, 2024 (F1). The reported sale prices are weighted averages with price ranges provided in the filing (F2–F4). The option shares were fully vested and exercisable (F5). The filer offers to provide per-price breakdowns on request.
• Shares owned following the reported transactions: not specified in the provided filing excerpt.
• Timeliness: filing date and period of report are both 2026-04-29; no late filing is indicated in the document excerpt.

Context

• This filing shows an option exercise coupled with same-day open-market sales (often a cashless outcome when exercised shares are sold). The separate $0.00 derivative disposal line may reflect a net settlement or share surrender related to the exercise or tax withholding; the filing does not explain that line further. All sales were executed under an established 10b5-1 plan, which schedules trades in advance and is generally viewed as routine.